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Ewing’s sarcoma (ES) and primitive 
neuroectodermal tumour (PNET) are 
now considered to be the same tu-
mour and usually occur in long bones. 
Extraskeletal Ewing’s sarcoma is an 
extremely rare neoplasm, accounting 
for 1% of soft tissue sarcomas, with 
most common location in the thorax. 
Gallbladder cancer (GBC) represents 
the most common type among the 
biliary tract cancers with a poor prog-
nosis even among patients undergo-
ing aggressive therapy.
We present study of extraskeletal ES/
PNET found in the hilus of the liver of 
an elderly, diagnosed one month pri-
or with GBC woman. The patient un-
derwent two cycles of chemotherapy 
SAIME/SAVAC for ES and thereafter 
was operated. During three-year fol-
low-up no recurrence of ES/PNET has 
been reported. However, two years 
after chemotherapy the patient suf-
fered a relapse of adenocarcinoma of 
the gallbladder and thus received pal-
liative chemotherapy of gemcitabine 
and cisplatin. After 16 months of re-
currence she died. To the best of our 
knowledge, this is the first case of ES/
PNET located in the hilus of the liver 
and as a synchronous neoplasm.
Key words: extraskeletal Ewing’s sar-
coma, PNET, hilus of liver, gallbladder 
carcinoma.
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Introduction
The Ewing’s sarcoma (ES) family of tumours includes ES and primitive 
neuroectodermal tumour (PNET), which are primary malignant small round 
cell tumours of bone and soft tissue. ES and PNET have a similar neuronal 
phenotype and, because they share an identical chromosome translocation, 
they should be viewed as two variants of the same tumour that differ only 
in their degree of neuronal differentiation. Tumours that demonstrate neu-
ronal differentiation are labeled PNETs, and those that are undifferentiated 
are diagnosed as ES. This distinction has no clinical significance [1]. However, 
characteristics and outcomes differ among patients with extraskeletal ES/
PNET in comparison with those with skeletal ES/PNET (Table 1) [2–4]. ES/
PNETs represent 1% of soft tissues sarcomas [2]. This neoplasm has been 
reported in various locations, but to the best of our knowledge, the case 
in question is the first case of ES/PNET located in the hilus of liver and as 
a synchronous neoplasm. 
Gallbladder carcinoma represents the most common and aggressive type 
among the biliary cancers. It occurs two to six times more often in women 
and its rate increases with age. About 90% of cases are connected with gall-
stone disease. The most frequent type of the tumour is adenocarcinoma 
that accounts for more than 80% of gallbladder cancers [5]. The simultane-
ous occurrence of gallbladder adenocarcinoma and other malignancies has 
been reported only in a few cases involving the coexistence of adenocarci-
noma of pancreas, lymphoma of mucosa associated lymphoid tissue of the 
gallbladder, hepatocellular carcinoma, uterine endometrioid adenocarcino-
ma and ovarian endometrioid carcinoma [6–9].
Case report 
Laparoscopic simple cholecystectomy was performed in a 70-year old fe-
male due to the chronic cholelithiasis. The postoperative abdominal ultra-
sound was free of any suspicious changes. Pathological examination of the 
gallbladder specimen revealed the presence of adenocarcinoma. One month 
later, a hypoechogenic mass of 54 × 52 × 43 mm located in the hilus of the 
liver was found on control ultrasonography (USG) and computed tomography 
(CT) of the abdomen (Fig. 1A). Computed tomography of the chest was free of 
any changes. The patient stayed asymptomatic with performance status (PS) 
0 at that time. This lesion was diagnosed as ES/PNET after core biopsy under 
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sonographic control. Skeletal scintigraphy showed no ab-
normalities. The patient underwent 2 cycles of intravenous 
chemotherapy according to the protocol of British Colum-
bia Cancer Agency (BCCA) for ES/PNET – SAIME (etoposide 
100 mg/m2, mesna 720 mg/m2, ifosfamide 1800 mg/m2) 
given for 5 consecutive days every 3 weeks alternating 
with SAVAC (vincristine 1.5 mg/m2, doxorubicin 75 mg/m2, 
cyclophosphamide 1200 mg/m2) given over one day every 
3 weeks. Control CT scans after two cycles showed a 57% 
tumour mass reduction in the biggest dimension (Fig. 
1B). Thereafter, the patient was operated and resection of 
the hilus of the liver, hepato-duodenal ligament and local 
lymph nodes was performed. The patient stayed asymp-
tomatic under regular control of every 3 months. Two years 
later, a mass of 46 × 25 mm between inferior vena cava, 
left liver lobe and the head of the pancreas, and a second 
mass of 17 × 14 mm in the common bile duct were revealed 
on the control CT (Fig. 1C). The patient’s PS was 2 and she 
Table 1. Comparison of skeletal and extraskeletal ES clinical features. 
Skeletal ES Extraskeletal ES
Age onset Most often in 2nd decade Usually under 35 years, mostly 2nd and 3rd decade
Sex predominance Male Male or female
Location Long bones (diaphysis) Thorax (32%), extremities (26%), head and neck (18%), 
retroperitoneum and pelvis (16%)
Symptoms In 40% patients: pain, enlargement of the extremity, 
infection- like with increased body temperature 
1/4–1/3 patients at diagnosis have metastatic disease 
(most common in lungs and bones)
In one third of patients pain, polisymptomatic 
(depending on the location)
Treatment CTH (chemotherapy) with RTH (radiotherapy) play 
main role, surgery as additional treatment
No standards, multimodal considered to be the best 
approach – CTH plus local treatment (surgery/RTH)
5-year survival rate 60–70% when localized, 20–40% when metastatic 38–83% 
Negative 
prognostic factors
Metastatic disease, size > 5 cm, located in pelvis and 
chest, infiltrating soft tissues, elevated LDH (lactate 
dehydrogenase)
Metastatic disease, elderly, pelvic location, incomplete 
resection, tumor size ≥ 8 cm, elevated LDH, poor 
histological response to CTH, RTH only as local 
treatment, positive surgical margins
Positive prognostic 
factors
Female, treatment within 1 month of diagnosis Normal level of hemoglobin, LDH, complete response to 
CTH, younger age, total resection, type 1 of the fusion 
EWS/FLI 1, located in the extremities, adjuvant RTH
Fig. 1. A) Hepatic tumor infiltrating head of the pancreas, 
vena cava inferior and portal vein. B) Subsequently per-
formed CT revealed regression of the tumor. C) Tumor infil-





Table 2. Primary antibodies used for immunohistochemical analysis
Specificity Clone Manufacturer Dilution Antigen retrieval
CK7 OV-TL12/30 DACO 1 : 50 citrate buffer
CK18 DC10 DACO 1 : 50 citrate buffer
LCA ZB11+PD7 DACO 1 : 100 citrate buffer
EMA E29 DACO 1 : 100 –
chromogranin DAK-A3 DACO 1 : 600 citrate buffer
synaptophysin SY38 DACO 1 : 100 EDTA
vimentin V9 DACO 1 : 50 citrate buffer
desmin D33 DACO 1 : 50 citrate buffer
NSE BBS/NC/VI/H14 DACO 1 : 100 citrate buffer
TTF1 8G7G3/1 DACO 1 : 500 citrate buffer
CD117 policl. DACO 1 : 100 EDTA
S100 policl. DACO 1 : 400 –
Ki-67 MIB1 DACO 1 : 200 citrate buffer
MyoD1 5.8A DACO 1 : 50 citrate buffer
presented with jaundice. She underwent ERCP (endoscop-
ic retrograde cholangio-pancreatography) with insertion of 
the stent to the common bile duct. Core biopsy revealed 
the recurrence of gallbladder adenocarcinoma with infiltra-
tion of the pancreas. Metastatic lesion was also presented 
in the liver on subsequently performed control CT. The pa-
tient underwent palliative intravenous chemotherapy of 
cisplatin (25 mg/m2) and gemcitabine (1000 mg/m2) given 
both on the first and eighth day of the cycle repeated every 
3 weeks. Partial regression according to RECIST (Response 
Evaluation Criteria in Solid Tumours) 1.1 of the lesions locat-
ed in the hilus of the liver and left liver lobe was observed 
on control CT scan after 2 cycles of chemotherapy and thus 
chemotherapy has been continued till 6 cycles. After that 
time stable disease on control CT of the abdomen has been 
observed. One month later the patient’s PS was 4 and she 
presented again with jaundice. A flow-restoring procedure 
was performed on the intra-biliary stent. The patient was 
admitted to the palliative care department, where she died. 
No postmortem examination was conducted.
Material and methods
Biopsy materials were examined with usage of forma-
lin fixed, paraffin wax embedded tissue stained routinely 
with hematoxilin and eosine (HE). Immunohistochemistry 
included antibodies to cytokeratine 7 (CK7), cytokeratine 
18 (CK18), leucocyte common antigen (LCA), epithelial 
membrane antigen (EMA), chromogranin, synaptophysin, 
vimentin, desmin, neurone specific enolase (NSE), thy-
roid transcription factor (TTF), cluster differentiation 117 
(CD117), S-100 protein, Ki67 and MyoD1.
A wide panel of immunohistochemical stainings was 
performed to exclude the diseases within the scope of the 
differential diagnosis of Ewing’s sarcoma. Briefly, a repre-
sentative HE section was selected for immunohistochemi-
cal investigation and 4 µm sections were prepared. The im-
munohistochemistry was performed by standard method: 
the slides were de-waxed, rehydrated and incubated in 3% 
peroxide solution for 10 minutes to block the endogenous 
peroxidase activity. Antigen retrieval was carried out by 
microwaving in citrate buffer (pH = 6) or EDTA (pH = 8) for 
5 minutes at 700 W, then for 5 minutes at 600 W. The Lab-Vi-
sion detection system was used. The primary antibodies and 
the respective technical details are summarised in Table 2.
Results
Removed gallbladder, length 11 cm, with thickened wall, 
filled with gallstones was sent for the histological exam-
ination. This revealed the presence of adenocarcinoma 
with infiltration of muscularis propria, T1bNxM0 (Fig. 2A). 
An operative margin was free of cancer but a small group 
of cancer cells was visible in the lumen of the gallbladder 
at the resection margin. Most probably this finding was 
irrelevant and the cancer cells were placed there when cut-
ting the material.
Microscopic examination of the lesion located in the 
hilus of the liver, diagnosed as ES/PNET showed a small 
cell neoplasm with membranous expression of CD99, NSE, 
vimentin and synaptophysin. Proliferative activity defined 
as the percentage of cells positive in Ki67 was higher than 
90%. Staining for CK7, CK18, LCA, EMA, chromogranin, 
TTF1, CD117 and S-100 protein were negative. Expression 
of MyoD1 was weak, cytoplasmatic and not characteristic 
for neoplasms of muscular origin (Fig. 2B–D). After che-
motherapy for ES/PNET, examination of the specimens 
removed within surgery has revealed inflammatory cell in-
filtration and necrosis with no presence of neoplastic cells. 
The histological picture together with the results of immu-
nohistochemical reactions were consistent with ES/PNET, 
which is a highly cellular neoplasm consisting of sheets 
and nests of small, uniform, round or polygonal cells with 
scanty cytoplasm and usually high mitotic activity.
Discussion
Presented case report highlights an extremely rare type 
of soft tissue sarcoma within atypical location. Unusual is 
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also elderly age of the patient and existence of GBC in the 
same region as a synchronous neoplasm. Additionally, this 
case documents pathological diagnosis of ES/PNET, which 
is based on both histology and immunohistochemistry (the 
gold standard) and may be problematic due to the rarity of 
these tumours and no typical location [10]. Core biopsy, as it 
has been shown, is usually sufficient for making diagnosis. 
Immunohistochemistry is essential as the family of small 
round cell tumours is large and includes a lot of different 
neoplasms, for instance, non-Hodgkin lymphoma, neu-
roblastoma, alveolar rhabdomyosarcoma, mesenchymal 
chondrosarcoma, retinoblastoma and desmoplastic small 
round cell tumour. Membranous expression of CD99 coex-
isting with positive expression of NSE or synaptophysin are 
sufficient for the diagnosis of ES/PNET. Other negative im-
munohistochemical reactions (for instance LCA, MyoD1) are 
helpful in eliminating neoplasms from the small round cell 
tumours family [1, 10]. Genetic studies are useful because 
translocation t(11;22)(q24;q12) and expression of a fusion 
gene EWS-FLI1 are specific for ES/PNETs but they are not 
always available [11]. It should be borne in mind that up 
to 15% of ES/PNETs can be negative for this translocation, 
which is connected with presence of other rare mutations. 
It is also known that the presence of this translocation is 
not likely to be considered diagnostic of ES and PNET in the 
absence of supporting histological evidence [12].
Treatment of EES/PNET usually includes multimodal 
chemotherapy combined with aggressive surgical treat-
ment or radiotherapy [13]. In contrast to ES/PNET, surgery 
plays a major role [14]. Multi-agent chemotherapy is su-
perior to single agent one, includes cyclophosphamide, 
ifosfamide, etoposide, doxorubicin, vincristine, and should 
be given 12–24 weeks before operation [15]. The present-
ed patient was treated with multimodal chemotherapy 
of BCCA. Surgery should be performed after neoadjuvant 
chemotherapy because the probability of achieving com-
plete resection with microscopic free margins is increased. 
In our case chemotherapy resulted in the regression on CT 
imaging and finally, necrosis of the neoplasm, which was 
a sign of good response to the treatment and could be 
considered as a good prognostic factor. The recommended 
operation is a wide resection encompassing a rim of 2–3 cm 
of normal tissue. When resection is either incomplete or 
impossible, radiotherapy is an alternative with the same 
Fig. 2. A) Gallbladder wall with exophytic part of adenocarcinoma; HE, magnification 5×. B) Histological picture of PNET localised within 
hilus of the liver: sheets of small, uniform, polygonal cells with scanty cytoplasm; HE, magnification 20×; C) Immunohistochemistry for 
CD99; membranous staining in PNET cells, magnification 20×; D) Immunohistochemistry for synaptophysin: positive, cytoplasmic, granular 




dosage as in ES/PNET [14]. The value of adjuvant chemo-
therapy in clinical improvement remains not clear [15].
About 30–40% of patients with ES experience recur-
rence. The rate for patients with EES remains unclear and 
might be similar [15]. Therapy for refractory or relapsed dis-
ease consists of participation in clinical trials, chemothera-
py with/without radiotherapy and surgery, if possible. New 
strategies for the treatment of ES/PNET include stem cell 
transplantation, antiangiogenic agents (bevacizumab, vin-
blastine, celecoxib), mTOR pathway inhibition (sirolimus), 
bisphosphonates, anti-insulin-like growth factor receptor 
1 (IGFR1) agents (cixutumumab, R1507) and anti-CD99 
agents [16].
At our patient no recurrence of PNET/EES has been 
reported within 42 months after diagnosis till her death, 
which was caused by the relapse of the GBC. Complete 
resection is the only potential curative treatment of GBC, 
however only 10% of patients are considered candidates 
for surgical treatment. Data concerning treatment of T1b 
stage disease are scant, however National Comprehensive 
Cancer Network recommends in this case radical chole-
cystectomy [17]. Even for a patient undergoing aggressive 
surgery, a 5-year survival rate is mere 5–10%. Several ret-
rospective reports suggest beneficial effects of both adju-
vant and neoadjuvant (chemo)radiotherapy. In relapsed 
disease, palliative chemotherapy should be considered. 
Combination of cisplatin and gemcitabine has been used 
as a standard treatment because it has been shown to in-
crease survival rate (11.7 vs. 8.1 months) comparing with 
gemcitabine as the only agent [18].
Summing up, this case confirms that EES/PNET is a che-
motherapy-sensitive neoplasm. The most beneficial thera-
py for this tumour remains systemic treatment combined 
with surgery. New strategies of treatment for EES/PNET 
are under investigation and thus hopeful. Unfortunately, 
the overall survival of patients with GBC remains poor 
and the recurrence rate is still high. That is why this major 
challenge in oncology requires the initiation of new clini-
cal efforts and trials as well as the integration of the ones 
conducted previously. 
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